Nakamura, Yoshiaki
Taniguchi, Hiroya http://orcid.org/0000-0003-1407-6682
Ikeda, Masafumi http://orcid.org/0000-0002-4050-2086
Bando, Hideaki http://orcid.org/0000-0001-5041-2765
Kato, Ken http://orcid.org/0000-0002-1733-5072
Morizane, Chigusa
Esaki, Taito
Komatsu, Yoshito
Kawamoto, Yasuyuki
Takahashi, Naoki
Ueno, Makoto http://orcid.org/0000-0003-4480-0029
Kagawa, Yoshinori
Nishina, Tomohiro
Kato, Takeshi
Yamamoto, Yoshiyuki
Furuse, Junji
Denda, Tadamichi
Kawakami, Hisato http://orcid.org/0000-0002-3280-4850
Oki, Eiji http://orcid.org/0000-0002-9763-9366
Nakajima, Takako
Nishida, Naohiro
Yamaguchi, Kensei
Yasui, Hisateru
Goto, Masahiro http://orcid.org/0000-0003-4279-8682
Matsuhashi, Nobuhisa
Ohtsubo, Koushiro
Yamazaki, Kentaro
Tsuji, Akihito http://orcid.org/0000-0003-4034-1945
Okamoto, Wataru
Tsuchihara, Katsuya
Yamanaka, Takeharu
Miki, Izumi
Sakamoto, Yasutoshi
Ichiki, Hiroko
Hata, Masayuki
Yamashita, Riu
Ohtsu, Atsushi
Odegaard, Justin I.
Yoshino, Takayuki http://orcid.org/0000-0002-0489-4756
Article History
Received: 14 April 2020
Accepted: 18 August 2020
First Online: 5 October 2020
Competing interests
: N.T., N.M., K.O., W.O., I.M., Y.S., H.I. and M.H. declare no competing interests. Y.N. reports research funding from Taiho Pharmaceutical. H.T. reports honoraria from Bayer, Sanofi, Takeda, Chugai, Taiho Pharmaceutical, Lilly Japan, Merck Serono, Yakult Honsha, MBL, Bristol-Myers Squibb, MSD, Novartis, Daiichi Sankyo, Mitsubishi Tanabe Pharma and Nippon Kayaku; and research funding from Sumitomo Dainippon Pharma, Array BioPharma, MSD Oncology, Ono Pharmaceutical, Daiichi Sankyo, Sysmex, Novartis and Takeda. M.I. reports honoraria from Bayer, Bristol-Myers Squibb, Eli Lilly, Eisai, Sumitomo Dainippon Pharma, EA Pharma, Gilead, Teijin Pharma, Yakult, Taiho, Nobelpharma, Otsukam MSD, Mylan, NIHON SERVIER and Astellas; advisory roles with Bayer, Bristol-Myers Squibb, Eli Lilly, Eisai, Chugai, Teijin Pharma, Kyowa Hakko Kirin, NanoCarrier and Shire; and research funding from Bayer, Bristol-Myers Squibb, Eli Lilly, Eisai, Takeda Pharmaceutical, AstraZeneca, Chugai, Merck Serono, ASLAN, Daiichi Sankyo, Novartis, Kyowa Hakko Kirin, NanoCarrier, Yakult, Taiho, Baxalta, Ono Pharmaceutical and J-Pharma. H.B. reports honoraria from Taiho Pharmaceutical, Lilly Japan, Takeda Pharmaceutical, Chugai, Sanofi and Yakult Honsha; and research funding from AstraZeneca and Sysmex. K.K. reports research funding from Ono Pharmaceutical, MSD, Shionogi, Merck Bio, Oncolys Biopharma and Beigene. C.M. reports honoraria from Novartis, Yakult Honsha, Teijin Pharma, Taiho Pharmaceutical, Eisai and MSD; advisory roles with Yakult Honsha, Novartis, Taiho Pharmaceutical and Abbvie; and research funding from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca and Merck biopharma. T.E. reports honoraria from Eli Lilly and Chugai; and research funding from Novartis, Merck Serono, Sumitomo Dainippon Pharma, Ono Pharmaceutical, Daiichi Sankyo, MSD, Astellas, Parexel International, Amgen Astellas BioPharma and IQVIA. Y. Komatsu reports honoraria from Asahi Kasei Pharma, Bayer Yakuhin, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Kyowa Kirin, Medical Review, Merck Biopharma, Mitsubishi Tanabe Pharma, Moroo, Nipro, Ono Pharmaceutical, Pfizer Japan, Sanofi, Shire Japan and Taiho Pharmaceutical; and research funding from A2 Healthcare, Asahi Kasei Pharma, Astellas Pharma, Bayer Yakuhin, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Mediscience Planning, NanoCarrier, Ono Pharmaceutical, Parexel International, Sanofi-aventis, Shionogi & Co., Ltd, Taiho Pharmaceutical, Yakult Honsha, Incyte, IQVIA, MSD, Nippon Zoki Pharmaceutical, Syneos Health Clinical and Sysmex. Y. Kawamoto reports honoraria from Taiho Pharmaceutical, Takeda, Chugai, Daiichi Sankyo, Merck Serono and Lilly. M.U. reports honoraria from Taiho Pharmaceutical, Yakult Honsha, AstraZeneca, Teijin Pharma, Merck Serono, Nipro Corporation, MSD and Daiichi Sankyo; and research funding from Astellas Pharma, Taiho Pharmaceutical, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical, MSD, Merck Serono, Sumitomo Dainippon Pharma, Incyte, ASLAN Pharmaceutical and Yakult Honsha. Y. Kagawa reports honoraria from Chugai, Taiho Pharmaceutical, Bayer Yakuhin Japan, Eli Lilly, Yakult Honsha, Takeda Pharmaceutical, Ono Pharmaceutical and Merck Biopharma. T. Nishina reports honoraria from Taiho Pharmaceutical, Chugai, Ono Pharmaceutical, Bristol-Meyers Squibb and Lilly; and research funding from Taiho Pharmaceutical, Chugai, Daiichi Sankyo, MSD, Ono Pharmaceutical, Bristol-Meyers Squibb, Lilly and Sumitomo Dainippon Pharma. T.K. reports honoraria from Chugai, Yakult Honsha, Ono Pharmaceutical, Bayer, Takeda, Lilly Japan, Taiho Pharmaceutical, Mochida Pharmaceutical, Merck Serono and Asahi Kasei; and research funding from Chugai. Y.Y. reports honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Asahi Kasei, Sanofi, Nihonkayaku, Merck Serono and Yakult, Eisai. J.F. reports honoraria from Eisai, Bayer Yakuhin, Taiho Pharmaceutical, Ono Pharmaceutical, Novartis, Yakult Honsha, Teijin Pharma, Shionogi, EA Pharma, Eli Lilly Japan, Takeda, Chugai, Mochida Pharmaceutical, Nihon Servier, Sanofi, Fujifilm Toyama Chemical, Nobelpharma, Pfizer, Sawai Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, Merck Serono, Nippon Kayaku, MSD, Shire and Kyowa Hakko Kirin; advisory roles with Eisai, Fujifilm, Ono Pharmaceutical, Yakult Honsha, MSD, Merck Bio and J-Pharma; and research funding from Ono Pharmaceutical, MSD, Sumitomo Dainippon Pharma, J-Pharma, Yakult Honsha, AstraZeneca, Daiichi Sankyo, Eisai, Bayer, Pfizer, NanoCarrier, Kyowa Hakko Kirin, Taiho Pharmaceutical, Chugai, Sanofi, Takeda, Mochida Pharmaceutical, Astellas Pharma and Eli Lilly Japan. T.D. reports honoraria from Sawai Pharmaceutical; a speakers’ bureau with Sysmex; and research funding from MSD and Ono Pharmaceutical. H.K reports honoraria from Bristol-Myers Squibb, AstraZeneca, Bayer, Eli Lilly Japan, MSD, Ono Pharmaceutical, Chugai, Daiichi Sankyo, Takeda Pharmaceutical and Taiho Pharmaceutical; lecture fees from Bristol-Myers Squibb, Eli Lilly Japan, MSD, Ono Pharmaceutical, Chugai, Takeda Pharmaceutical and Taiho Pharmaceutical; consulting fees from Bristol-Myers Squibb, Eli Lilly Japan, MSD, Ono Pharmaceutical, Daiichi Sankyo and Taiho Pharmaceutical Co. Ltd; and research funding from Chugai, Taiho Pharmaceutical and Eisai. E.O. reports honoraria from Chugai, Taiho Pharmaceutical, Bayer Yakuhin Japan, Eli Lilly, Yakult Honsha, Takeda Pharmaceutical, Ono Pharmaceutical and Merck Biopharma. T. Nakajima reports honoraria from Celltrion Healthcare Japan, Taiho Pharmaceutical, Merck Serono, Chugai, Takeda Pharmaceutical, Sanofi, Daiichi Sankyo, Eli Lilly Japan, Nippon Kayaku, Ono Pharmaceutical, MSD, Sawai Pharmaceutical, Bayer Yakuhin, Bristol-Myers Squibb, Teijin Pharma, Pfizer Japan, Novartis Japan, Yakult Honsha and Nipro; advisory roles with Bristol-Myers Squibb and Taiho Pharmaceutical; and research funding from Ono Pharmaceutical, MSD, Astellas Pharma, Sumitomo Dainippon Pharma, Eisai, Nippon Kayaku, Solasia Pharma, Chugai, Taiho Pharmaceutical, Daiichi Sankyo, Sanofi, Merck Serono, Daiichi Sankyo, Takeda Pharmaceutical and Eli Lilly Japan. N.N. reports research funding from Chugai, Yakult Honsha and Ono Pharmaceutical. K. Yamaguchi reports advisory roles with Bristol-Myers Squibb and Daiichi Sankyo; speakers’ bureaux with Chugai, Merck Serono, Bristol-Myers Squibb, Taiho Pharmaceutical, Lilly, Ono Pharmaceutical and Daiichi Sankyo; and research funding from Ono Pharmaceutical, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Daiichi Sankyo, Lilly, Gilead Sciences, Yakult Honsha, Chugai, Boehringer Ingelheim, Eisai and MSD. H.Y. reports honoraria from Taiho Pharmaceutical, Chugai, Bristol-Myers Squibb, Daiichi Sankyo, Terumo, Eli Lilly Japan, Merck Biopharma, Yakult Honsha and Bayer Yakuhin; and research funding from MSD, Daiichi Sankyo and Ono Pharmaceutical. M.G. reports honoraria from Yakult Honsha, Taiho Pharmaceutical, Daiichi Sankyo, Eisai and Ono Pharmaceutical; and research funding from Chugai, Taiho Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical and Eli Lilly. K. Yamazaki reports honoraria from Chugai, Daiichi Sankyo, Yakult Honsha, Takeda, Bayer, Merck Serono, Taiho Pharmaceutical, Lilly, Sanofi, Ono Pharmaceutical, MSD and Bristol-Myers Squibb. A.T. reports speakers’ bureaux with Taiho Pharmaceutical, Chugai, Eli Lilly Japan, Merck Serono, Sanofi and Bristol-Myers Squibb; and research funding from Taiho Pharmaceutical, Sanofi and Ono Pharmaceutical. K.T. reports honoraria from SRL Diagnostics, DNA Chip Research, Chugai, Novartis, Takeda, MSD, Sysmex, Nippon Kayaku, Illumina, Fujitsu, Varian Medical Systems, Miyarisan Pharmaceutical, Bristol-Myers Squibb, AstraZeneca and Novartis. T. Yamanaka reports honoraria from Chugai, Bayer, Boehringer Ingelheim and Takeda; and research funding from Chugai, Bayer and Mochida. R.Y. reports honoraria from Takeda Pharmaceutical. A.O. reports personal fees from Bristol-Myers Squibb, Ono Pharmaceutical, Taiho Pharmaceutical and Chugai; and a grant from Bristol-Myers Squibb. J.I.O. reports employment from, and stock interests in, Guardant Health. T. Yoshino reports research funding from Novartis Pharma, MSD, Sumitomo Dainippon Pharma, Chugai, Sanofi, Daiichi Sankyo, Parexel International, Ono Pharmaceutical and GlaxoSmithKline.